ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of 37.27 billion. The enterprise value is 36.70 billion.
| Market Cap | 37.27B |
| Enterprise Value | 36.70B |
Important Dates
The last earnings date was Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.43% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 144.78M |
Valuation Ratios
The trailing PE ratio is 25.08 and the forward PE ratio is 22.00.
| PE Ratio | 25.08 |
| Forward PE | 22.00 |
| PS Ratio | 6.90 |
| PB Ratio | 5.90 |
| P/TBV Ratio | 13.09 |
| P/FCF Ratio | 20.80 |
| P/OCF Ratio | 19.47 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.75, with an EV/FCF ratio of 20.48.
| EV / Earnings | 24.70 |
| EV / Sales | 6.80 |
| EV / EBITDA | 17.75 |
| EV / EBIT | 19.84 |
| EV / FCF | 20.48 |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.06 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 0.47 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 26.60%.
| Return on Equity (ROE) | 25.68% |
| Return on Assets (ROA) | 14.75% |
| Return on Invested Capital (ROIC) | 26.60% |
| Return on Capital Employed (ROCE) | 25.44% |
| Weighted Average Cost of Capital (WACC) | 8.87% |
| Revenue Per Employee | 509,257 |
| Profits Per Employee | 140,177 |
| Employee Count | 10,600 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, ResMed has paid 332.81 million in taxes.
| Income Tax | 332.81M |
| Effective Tax Rate | 18.30% |
Stock Price Statistics
The stock price has increased by +29.49% in the last 52 weeks. The beta is 0.88, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | +29.49% |
| 50-Day Moving Average | 24.68 |
| 200-Day Moving Average | 20.83 |
| Relative Strength Index (RSI) | 68.13 |
| Average Volume (20 Days) | 13,077 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.60 |
Income Statement
In the last 12 months, ResMed had revenue of 5.40 billion and earned 1.49 billion in profits. Earnings per share was 10.11.
| Revenue | 5.40B |
| Gross Profit | 3.32B |
| Operating Income | 1.85B |
| Pretax Income | 1.82B |
| Net Income | 1.49B |
| EBITDA | 2.02B |
| EBIT | 1.85B |
| Earnings Per Share (EPS) | 10.11 |
Balance Sheet
The company has 1.42 billion in cash and 847.72 million in debt, with a net cash position of 569.35 million.
| Cash & Cash Equivalents | 1.42B |
| Total Debt | 847.72M |
| Net Cash | 569.35M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.32B |
| Book Value Per Share | 43.39 |
| Working Capital | 2.57B |
Cash Flow
In the last 12 months, operating cash flow was 1.91 billion and capital expenditures -122.89 million, giving a free cash flow of 1.79 billion.
| Operating Cash Flow | 1.91B |
| Capital Expenditures | -122.89M |
| Free Cash Flow | 1.79B |
| FCF Per Share | n/a |
Margins
Gross margin is 61.47%, with operating and profit margins of 34.19% and 27.53%.
| Gross Margin | 61.47% |
| Operating Margin | 34.19% |
| Pretax Margin | 33.69% |
| Profit Margin | 27.53% |
| EBITDA Margin | 37.51% |
| EBIT Margin | 34.19% |
| FCF Margin | 33.19% |
Dividends & Yields
ResMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.43% |
| Shareholder Yield | 0.43% |
| Earnings Yield | 3.99% |
| FCF Yield | 4.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ResMed has an Altman Z-Score of 12.89 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.89 |
| Piotroski F-Score | 6 |